Sali e Derivati degli API

<p>Applications Riociguat is used in the treatment for pulmonary hypertension.<br>References Frey, R. et al.: J. Clin. Pharmacol., 51, 1051 (2011);<br></p>

<p>Stability Hygroscopic<br>Applications A drug used for the treatment of atrial fibrillation and atrial flutter in patients who have suffered cardiac arrhythmias.<br>References Singh, B., et al.: J. Cardiovas. Pharmacol., 52, 300 (2008), Hoy, S., et al.: Drugs, 69, 1647 (2009), Hohnloser, S., et al.: New Eng. J. Med., 360, 668 (2009),<br></p>

<p>Applications A labelled antihypertensive. An angiotensin converting enzyme (ACE) inhibitor, converted to active, diacid metabolite.<br>References Teetz, V., et al.: Arzneim.-Forsch., 34, 1399 (1984), Ruggenenti, P., et al.: Lancet, 352, (1998), Bosch, J., et al.: Br. Med. J., 324, 1 (2002),<br></p>

<p>Applications 4-(3-Aminophenyl)-3-morpholinone is an intermediate during the preparation of imidazothiazoles as protein kinase inhibitors for treating cancers.<br>References Bamaung, N., et al.: PCT Int. Appl. (2009), WO 2009070516 A1 20090604.<br></p>

<p>Applications Edaravone D5 is the labelled compound of Edaravone(E335000). synthesized and used for relative quant. anal. of oligosaccharides by mass spectrometry (MS). Edaravone inhibits the disease activity in rheumatoid arthritis. Edaravone can significantly enhance IR flap viability and protect flap vessels, which is related to scavenging oxygen free radicals, reducing the consumption of SOD, reducing the extent of lipid peroxidation and inflammation, and protecting functional structure of vessels in the early stages of reperfusion. It also shows protective effects against STZ-induced cognitive impairment, oxidative stress, cholinergic dysfunction and altered protein expressions. Its acts like a free radical scavenger, decreased apoptotic cell death, oxidative damage to DNA and lipids, and angiogene<br>References Zhang, Ping, et al.: Anal. Biochem., 418, 1(2011)<br></p>

<p>Impurity Leflunomide EP Impurity H<br>Stability Hygroscopic<br>Applications 2-Cyano-N-[4-(trifluoromethyl)phenyl]acetamide (Leflunomide EP Impurity H) is used to prepare aminothiophene carboxylates and carboxamides as adenosine A1 receptor allosteric enhancers. It is also used to synthesize (1,2,3-triazol-4-yl)benzenamines as inhibitors against VEGF receptors 1 and 2.<br>References Nikolakopoulos, G., et al.: Bioorg. Med. Chem., 14, 2358 (2006); Kiselyov, A., et al.: Bioorg. Med. Chem. Lett., 19, 1344 (2009)<br></p>

<p>Stability Hygroscopic<br>Applications Edoxaban-d6 is the isotope labelled analog of Edoxaban (E555520); an anticoagulant drug which acts as a direct factor Xa inhibitor.<br>References Ruff, C., et al.: Am. Heart J., 160, 635 (2010); Ogata, K., et al.: J. Clin. Pharm., 50, 73 (2010)<br></p>

<p>Applications A labelled metabolite of Ramipril (R111000).<br>References Teetz, V., et al.: Arzneim.-Forsch., 34, 1399 (1984), Ruggenenti, P., et al.: Lancet, 352, (1998), Bosch, J., et al.: Br. Med. J., 324, 1 (2002),<br></p>

<p>Applications Bisdionin C is the derivative of Theobromine (T343800), which is a metabolite of Caffeine.<br>References Suto, M., et al.: Anticancer Drug Des., 6, 107 (1991), Burkart, V., et al.: Nat. Med., 5, 314 (1999), Hassa, P., et al.: J. Biol. Chem., 278, 45145 2003), Veres, B., et al.: J. Pharmacol. Exp. Ther., 310, 247(2004)<br></p>

<p>Stability Hygroscopic<br>Applications Ticagrelor, the first reversible oral P2Y12 receptor antagonist, provides faster, greater, and more consistent ADP-receptor inhibition than Clopidogrel. Used in the treatment of acute coronary syndromes (ACS).<br>References Matetzky, S., et al.: Circulation, 109, 3171 (2004), Bassand, J., et al.: Eur. Heart J., 28, 1598 (2007), Jakubowski, J., et al.: Cardiovasc. Drug Rev., 25, 357 (2007),<br></p>

<p>Applications A labelled antihypertensive. An angiotensin converting enzyme (ACE) inhibitor, converted to active, diacid metabolite.<br>References Teetz, V., et al.: Arzneim.-Forsch., 34, 1399 (1984), Ruggenenti, P., et al.: Lancet, 352, (1998), Bosch, J., et al.: Br. Med. J., 324, 1 (2002),<br></p>

<p>Applications An antihypertensive. Angiotensin converting enzyme (ACE) inhibitor.<br>References Brown, N.L., et al.: Eur. J. Pharmacol., 148, 79 (1988), Kober, L., et al.: N. Engl. J. Med., 333, 1670 (1995), Malik, R.A., et al.: Lancet, 352, 1978 (1998)<br></p>

<p>Applications An immunosuppressive. Inhibits T and B cell proliferation. Activity is attributed mainly to its metabolite, a malononitrile derivative, which is beleived to inhibit dihydroorotate dehydrogenase as well as several protein tyrosine kinases.This compound is suitable for dihydroorotate dehydrogenase (DHODH) related research.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Vrenken, T., et al.: J. Hepatol., 49, 799 (2008), Mazzucco, G., et al.: Clin. Nephrol., 70, 163 (2008), Davies, M., et al.: J. Med. Chem., 52, 2683 (2009),<br></p>

<p>Applications Riociguat-13C-d3 is the labelled analogue of Riociguat (R520000), which is used in the treatment for pulmonary hypertension.<br>References Frey, R. et al.: J. Clin. Pharmacol., 51, 1051 (2011);<br></p>

<p>Applications Macitentan, is an orally active endothelin receptor antagonist used for pulmonary arterial hypertension.<br>References Emoto, N. Ensho to Men'eki, 20, 487 (2012);<br></p>

<p>Applications Nonionic, injectable radio-contrast medium. Diagnostic aid (radiopaque medium).<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Muetzel, W., et al.: Am.J. Neuroradiol., 4, 350 (1983), Dawson, P., et al.: Acta Radiol. Diagn., 25, 253 (1984),<br></p>

<p>Applications Ethyl 2-Chloracetoacetate is used in the preparation of oxazoles and thiazoles as agonists for peroxisome proliferator-activated receptor δ. It is also used to synthesize dimethylimidazothiadiazolecarbohydrazides with anticancer activities.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Sznaidman, M., et al.: Bioorg. Med. chem. Lett., 13, 1517 (2003); Terzioglu, N., et al.: Eur. J. Med. Chem., 38, 781 (2003)<br></p>